Risk Factors and Management of Type 1 Diabetes
DOI:
https://doi.org/10.54097/t2vyt237Keywords:
T1D; factor; treatment; education.Abstract
Type 1 diabetes (TID) is an organ-specific autoimmune disease in which the selective destruction of islet B cells mediated by the T lymphocytes leads to absolute insulin deficiency, especially result from the interaction between genetic and non-genetic factors which is prevalent among teenagers all over the world. However, there also a lot of challenge in clinical and the trigger of the T1D.This essay comprehensively review the currently study of etiology, epidemiology, and management of T1D. he essay mainly aim at understanding the theory of disease as the result of improve in the therapeutic schedule. Moreover, recent innovation in immunotherapy especially in specific islet immune pathways and innovations in non-invasive blood glucose monitoring technologies make the therapy for the patient more efficient and more. At the same time, it is hoped that there will be more relevant studies in the future to continuously improve the understanding of its heterogeneity and prognostic markers, and improve and develop treatment strategies and management methods, so as to benefit patients.
Downloads
References
[1] Daneman D. Type 1 diabetes [J]. The Lancet, 2006, 367(9513): 847-858.
[2] DiMeglio L A, Evans-Molina C, Oram R A. Type 1 diabetes [J]. The Lancet, 2018, 391(10138): 2449-2462.
[3] Gillespie K M. Type 1 diabetes: pathogenesis and prevention [J]. Cmaj, 2006, 175(2): 165-170.
[4] Ziegler A G, Nepom G T. Prediction and pathogenesis in type 1 diabetes [J]. Immunity, 2010, 32(4): 468-478.
[5] Todd J A. Etiology of type 1 diabetes[J]. Immunity, 2010, 32(4): 457-467.
[6] Pociot F, McDermott M F. Genetics of type 1 diabetes mellitus [J]. Genes & Immunity, 2002, 3(5): 235-249
[7] Åkerblom H K, Vaarala O, Hyöty H, et al. Environmental factors in the etiology of type 1 diabetes [J]. American journal of medical genetics, 2002, 115(1): 18-29.
[8] Peng H, Hagopian W. Environmental factors in the development of Type 1 diabetes [J]. Reviews in endocrine and metabolic disorders, 2006, 7: 149-162.
[9] Xu Qing-Bo, Yang Yu, Yang Li, et al. Research progress of intestinal microbiota and type 1 diabetes mellitus [J]. Journal of Practical Medicine, 2019,39(2):142-147.
[10] Tang D Y. Endocrinology and Metabolism (3rd Ed.) Vol. Ii. People's Medical Publishing House.p1213.
[11] Yang Hongxiu, Leng Xuefi, Hu Situi, et al. Long-term follow-up of insulin pump therapy in children with type 1 diabetes [J]. Chinese Journal of Contemporary Pediatrics, 2019,23(2):116-120.
[12] Sims EK, Bundy BN, Stier K, Serti E, Lim N, Long SA, Geyer SM, Moran A, Greenbaum CJ, Evans-Molina C, Herold KC; Type 1 Diabetes TrialNet Study Group. Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. Sci Transl Med. 2021 Mar 3;13(583): eabc8980.
[13] Zhu M, Guo M, Li SC, et al. Progress in immunotherapy of type 1 diabetes mellitus [J]. Chinese Journal of Diabetes, 2018,16(1):101-105.
[14] Hermanns N, Ehrmann D, Finke‐Groene K, et al. Trends in diabetes self‐management education: where are we coming from and where are we going? A narrative review[J]. Diabetic Medicine, 2020, 37(3): 436-447.
[15] Lu Xuunyi, Feng Lanling, Wu Dongmei. Adolescents with type 1 diabetes diabetes pain related factors Meta analysis [J]. Journal of mental health in sichuan, 2024, 5 (2): 173-178.
[16] Chen Rong, Liu LIYong, Zou DJin. New techniques and strategies for non-insulin treatment of type 1 diabetes mellitus. Chinese Journal of Diabetes, 2018, 16(03):366-371.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Highlights in Science, Engineering and Technology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
